Publiée 2022-04-20
Mots-clés
- Post-COVID,
- syndrome,
- Editorial
(c) Copyright The Insight 2022
Ce travail est disponible sous la licence Creative Commons Attribution 4.0 International .
Comment citer
Résumé
Two and a quarter year have passed after the declaration of COVID-19 pandemic, yet the world continues to face new wave with new variant and its devastating effect on health. The world also faces its tremendous social and economic consequences, globally [1].
Healthcare mainly focuses on acute illness [2–4], long-term consequences have become evident [5,6]. Symptoms in COVID-19 may persist for several weeks after acute infection [7]. Symptoms persisting for more than three weeks after the diagnosis of COVID-19 characterize the post-COVID syndrome. Post-COVID syndrome is being increasingly recognized as a new clinical entity. Post-COVID syndrome was first described in spring 2020.
Post-COVID syndrome was first defined by Greenhalgh et al. as COVID-19 associated-illness extending for more than three weeks after the onset of symptoms. Currently, there is no universally accepted definition of post-COVID syndrome.
The incidence of post-COVID syndrome ranges from 10% to 35%, incidence increases as high as 85% in hospitalised patients and severe COVID-19 patients.
The most common post-COVID symptoms include fatigue, dyspnea, olfactory and gustatory dysfunction, chest pain, myalgia, and sleep and mental disorders [6–10].
There is no consensus on the classification of post-COVID syndrome. Multi-factorial pathogenesis, such as inflammation, nervous system dysfunction, endothelial damage, and thromboembolism are responsible for post-COVID syndrome.
As days are going, more and more post-COVID symptomes are recognised. Further research is needed in order to elucidate the incidence, clinical spectrum, pathogenesis, and prognosis of this new clinical entity.